Vericel Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $306.3M+29.1% YoYTTM through 30 Jun 2026
Net Income $24.2M+133.7% YoYTTM through 30 Jun 2026
Free Cash Flow $61.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 74.4% |
| EBITDA Margin | 10.2% |
| Operating Margin | 4.0% |
| Net Margin | 7.9% |
Returns
4.7%ROE
3.4%ROA
9.9%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio5.03x
Net Debt-$137.5Mnet cash position
Cash & Equivalents$125.4M
Quality Metrics
Altman Z-Score9.48
Piotroski F-Score6 / 9
FCF Margin20.1%
Rule of 4029.9
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $276.3M
Diluted EPS$0.48TTMFY2025: $0.32
Dividend
No dividend
Capital Allocation
R&D Spend$29.2M
Capex Intensity2.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| MACI | $239.5M | +21.0% | View detailsExpected to continue driving strong revenue and profit growth in 2026. |
| Burn Care | $36.8M | View detailsNexoBrid uptake continues to expand addressable market and drive Epicel utilization. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.